Figure 3

Estimated progression-free survival in patients with locally advanced/MBC with liver (a) and lung (b) metastases at baseline (pooled population). (a) Progression-free survival was similar in patients with baseline liver metastases regardless of treatment. (b) Similar results were seen in patients with baseline lung metastases. Control includes TPC and capecitabine; HR values and 2-sided 95% CIs were computed using Cox models with treatment as a covariate and stratified by study, region, prior capecitabine use, and HER2/neu status; nominal P values were based on log-rank tests and stratified as noted above. Medians were based on survival curves adjusted by study. CI, confidence interval; HR, hazard ratio; MBC, metastatic breast cancer; TPC, treatment of physician’s choice.